Redeye comments on Camurus' Q4 report 2025, which was below our estimates due to a large sequential sales decline of Buvidal sales in Europe...
Redeye provides its first take on Camurus’ Q4 report 2025, published this morning.
Redeye comments on Camurus' Q3 report 2025, which was below our estimates due to a sequential sales decline of Buvidal sales in Europe.
Redeye sees the phase I results from the controlled study of semaglutide monthly depot as a success, paving the way for future studies with ...
Redeye provides its first take on Camurus’ Q3 report 2025, published this morning.
Redeye comments on Camurus' Q2 report 2025, which was in line with our estimates on a constant currency basis.
Redeye provides its first take on Camurus’ Q2 report 2025, published this morning.
Redeye comments on the topline data from the phase II study POSITANO, which investigates the effect of CAM2029 in polycystic liver disease.
Redeye views the agreement with Eli Lilly, close second in the obesity space after Novo Nordisk, as strong validation of its FluidCrystal pl...
Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi sales were flat Q/Q on a constant FX ba...
Redeye provides its first take on Camurus’ Q1 report 2025, published this morning.
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annu...
